Olaparib
ACCRU-ICRN-1702
Phase 2 small_molecule active
Quick answer
Olaparib for Bile Duct Adenocarcinoma is a Phase 2 program (small_molecule) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Bile Duct Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active